Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
End-stage renal disease (ESRD) is a major global health problem, with millions of people dependent on hemodialysis and high mortality due to limited access to treatment. The prevalence of ESRD is expected to increase sharply in developing countries by 2030. Hemodialysis patients have a mortality rate much higher than that of the general population, primarily attributable to cardiovascular diseases (70% of deaths). Uremic toxins, which cause inflammation and oxidative stress, accelerate cardiovascular complications. Age and comorbidities such as hypertension and diabetes also worsen the prognosis.
This was a descriptive, retrospective, observational study conducted in the Nephrology-Hemodialysis Department of the Bogodogo University Hospital (CHU-B) between December 2020 and December 2024. All patients dialyzed for ESRD during this period were included, with the exception of four who started treatment elsewhere. Data, sourced from clinical records and registries, were analyzed using statistical tests (Student's t-test, Chi-square). Survival was assessed using the Kaplan-Meier method and Cox Regression analysis.
The study included 153 patients (an average of 88 patients per year), with a mean age of 47.1 years. Hypertension was the most frequent comorbidity (82.1%), followed by the combination of hypertension and diabetes (12.5%). Chronic Glomerulonephritis (CGN) was the primary nephropathy (75%). In total, 67 patients (43.8%) died. A significant difference was observed between genders: 55% of women died compared to 36.6% of men (p<0.01). Median survival was significantly lower in women (31 months) than in men (53 months). The analysis also showed an earlier occurrence of death in women.
This study confirms the high mortality of patients on chronic hemodialysis at CHU-B, with a death rate of 43.8% over the study period. It highlights a significantly poorer prognosis for women, whose median survival is much lower than that of men. Hypertension and CGN were the predominant pathologies in this cohort. These results underscore the need to enhance management strategies, particularly for women, and to better investigate specific risk factors to improve survival.
